Geode Capital Management
TTRX

Geode Capital Management’s Turn Therapeutics TTRX Stock Holding History

Geode Capital Management’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.9K Hold
17,142
– – ﹤0.01% 4292
2025
Q4 		$67.5K Buy
+17,142
New +$71.5K ﹤0.01% 4180

Other funds holding TTRX

DI
DDFG Inc Thousand Oaks, California $464M AUM 16.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
MMA
Miracle Mile Advisors Los Angeles, California $7.29B AUM 16.22% 1-Year Est. Return

Geode Capital Management's TTRX Position: Q1 2026 in Review

Geode Capital Management held its Turn Therapeutics (TTRX) position steady in Q1 2026 at 17,142 shares worth $54.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4292.

Geode Capital Management first reported a position in TTRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $67.5K in Q4 2025. 20 funds tracked by Wall St. Rank hold TTRX as of Q1 2026.

  • Geode Capital Management held 17,142 shares of Turn Therapeutics worth $54.9K as of Q1 2026.
  • Geode Capital Management left its Turn Therapeutics share count unchanged in Q1 2026.
  • Turn Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4292 holding.
  • Geode Capital Management first reported a position in Turn Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Geode Capital Management's Turn Therapeutics position peaked at $67.5K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Turn Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.